The way lymphotropic therapy in patients with open-angle glaucoma with normalized intraocular pressure

 

The invention relates to medicine, namely to ophthalmology, and for the treatment of patients with open-angle glaucoma with normalized intraocular pressure. For this lymphotropic in the mastoid introducing heparin in alternation with emoxipin on the background of intramuscular injection of nicotinic acid. The invention allows to significantly improve Central and peripheral vision patients while reducing complexity and morbidity of administration of drugs. 1 table, 1 Il.

The invention relates to medicine, namely to ophthalmology.

The known method parabulbar treatment emoxipin patients with open-angle glaucoma with normalized intraocular pressure (Y. C. Kramarenko et al. The emoxipin in the treatment of primary glaucoma, " Vestn. Oftalmol. - 1992. - 1. - S. 14-15). As access introduction emoxipin authors use parabulbar area.

The disadvantages of this method are the following: (1) It is quite traumatic as possible subcutaneous hematoma, perforation of the sclera and the introduction of drugs into the cavity of the eyeball. 2) vision Function as a result of treatment increase in visual acuity only in 33.3 which is a significant increase in Central and peripheral vision in patients with open-angle glaucoma with normalized intraocular pressure by reducing the complexity and traumatic introduction of the drug.

This objective is achieved in that when the drug is used lymphotropic area in the mastoid (C. M. Buyanov et al. Drug saturation of the lymphatic system. - Naukova Dumka, 1991. - S. 54-55). Experimentally proved: lymphotropic entered the isotope is in the optic nerve in a high concentration of more than 9 h (L. N. Tarasova et al. Experimental substantiation of the use of endolymphatic therapy postranecky intraocular purulent infection. //Ophthalmosurgery. - 1993. - 1. - S. 70-75). It is superior to other known methods of drug injection in the eye disease: intramuscular, intravenous, parabulbar, subconjunctival and retro-bulbar.

Comparison of the proposed method with the prototype allowed us to establish compliance with the criteria of the invention of "novelty", as the visual acuity improved in 84% of patients 0.140,01, field of view widened in 88% of patients 67o3o. The methodology is not traumatic, is not accompanied by side effects.

The use of such method of treatment of patients with open-angle glaucoma with normalized intraocular pressure is unknown.

Str is 1 cm inferior and lateral to his subcutaneously introduced emoxipin 1% - 1,0 through day 5, alternating with similar lymphotropic the introduction of heparin for 5 thousand IU every day 5 on each side (see drawing). Background therapy: nicotinic acid 1% - 1,0 intramuscularly 10.

An example of a specific application of the extract from the medical history of the patient C., 169/1999, 72, Diagnosed with open-angle IIA unstabilized glaucoma of the right eye, open-IIIA non-stabilized glaucoma of the left eye.

In 1999 produced deep sclerectomy on the left eye. The intraocular pressure of the left eye normalized. Over the next three months witnessed a deterioration of vision in both eyes on the background of normal intraocular pressure.

Upon receipt vis OD=0,4 sph-2,0 D=0,7.

vis OS=0,2 sph-2,0 D=0,3.

TOD=23 mm RT.article the instillation S. Ocupres E 0,25% 2 times a day every day.

TOS=18 mm RT.article without antihypertensive drugs.

The total field of view: OD - 360oOS - 110oTreatment. Lymphotropic in the mastoid heparin 5 thousand IU every day 5 in alternation with emoxipin 1% to 1.0 5 a day on each side, intramuscularly nicotinic acid 1% - 1,0 10 (table).

During treatment, the patient's health is good, no complaints were filed. Subjectively experienced improved vision in both eyes.

When is.

TOS=20 mm RT.article without antihypertensive drugs.

The total field of view: OD-405oOS-135o.

Using the proposed methodology 211 treated patients (360 eye).

Thus, the advantage of the proposed method over the known fact that along with the technical simplicity of visual functions in patients with open-angle glaucoma with normalized intraocular pressure increased more significantly (at parabulbar injections vision function improved in 33% of patients with lymphotropic introduction - in 84% of patients). The method is not accompanied by side effects that can be applied in outpatient practice.

Claims

Method of treatment of open-angle glaucoma with normalized intraocular pressure, different targeted action to improve visual acuity, field of vision and low invasiveness, involves the use of lymphotropic introduction to the mastoid heparin in alternation with emoxipin on the background of intramuscular injection of nicotinic acid.

 

Same patents:

The invention relates to the field of ophthalmology

The invention relates to new guanidinium heterocyclic compounds of the formula (I), where R1denotes H, alkyl or is absent when R1missing link (a) is a double bond, D represents CR2, R2selected from H, alkyl, halogen, or, when is a CR3D can be N, denotes NR9, CR3=CR8, CR3, S, where R9denotes H, alkyl, alkenyl or quinil and where R3and R8selected from H, alkyl, alkenyl, quinil or cyano, R4, R5, R6each independently selected from H, alkyl, alkenyl, quinil, cyano, halogen or NH-C(= NR10)OTHER11(guanidine), R10and R11selected from H, methyl and ethyl, and where only one of R1, R5and R6is guanidines, R7selected from H, alkyl, alkenyl, quinil and halogen
The invention relates to medicine, in particular to ophthalmology, and for the health of the retina and optic nerve in various pathologies of the eye
The invention relates to medicine, ophthalmology, to methods for treating glaucoma
The invention relates to medicine

The invention relates to medicine, intensive care medicine and surgery, can be used for the prevention and treatment of liver failure after surgery of the liver, accompanied by acute massive haemorrhage
The invention relates to medicine, Nephrology and can be used for the treatment of chronic glomerulonephritis
The invention relates to medicine, namely to ophthalmology, and is intended for the treatment of inflammatory diseases of the iris and ciliary body, accompanied fibrinous exudation
The invention relates to medicine, namely to surgery and traumatology, and for the treatment of frostbite
The invention relates to medicine, namely to methods provide emergency self - help and mutual aid and can be used to prevent complications from snake bites in field conditions

The invention relates to medicine, namely to vascular surgery, and is intended to prevent reocclusion operations in the great vessels

The invention relates to medicine, in particular for the treatment of patients with liver diseases, and the development of a treatment method that increases the effectiveness of therapy by improving the hemodynamics of the liver

The invention relates to medicine, in particular to pulmonology and Allergology and for the treatment of a patient suffering from antigen-induced asthma, and reduced hyperresponsiveness of the Airways

The invention relates to amino acid derivatives of the formula I

< / BR>
or its non-toxic salt or its hydrate, the pharmaceutical composition having inhibitory effect on calcium channel iv-type; the inhibitor calcium channel N-type; a pharmaceutical composition for prevention and/or treatment of cerebral infarction and pharmaceutical compositions for the treatment of pain
The invention relates to a new process for the preparation of omeprazole, which is effective as an inhibitor of the secretion of gastric acid and is useful as an antiulcer agent

the mammal, the pharmaceutical composition" target="_blank">

The invention relates to substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and substituted 2-(2,6-dioxopiperidin-3-yl)-occaisonaly, the method of reducing levels of tumor necrosis factorand treatment of inflammatory and autoimmune diseases in a mammal by introducing such derivatives, and to pharmaceutical compositions of such derivative
Up!